1BSL01AE — Biotika as Income Statement
0.000.00%
- €9.10m
- €6.62m
- €16.18m
Annual income statement for Biotika as, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 19.9 | 17.6 | 8.91 | 11 | 16.2 |
Cost of Revenue | |||||
Gross Profit | 11.1 | 9.91 | 7.03 | 5.74 | 7.97 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 18 | 15.5 | 8.44 | 12.1 | 16 |
Operating Profit | 1.94 | 2.16 | 0.472 | -1.08 | 0.163 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.5 | 2.73 | 0.515 | -0.843 | 0.221 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.02 | 2.28 | 0.406 | -0.82 | 0.369 |
Net Income Before Extraordinary Items | |||||
Net Income | 2.02 | 2.28 | 0.406 | -0.82 | 0.369 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.02 | 2.28 | 0.406 | -0.82 | 0.369 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.81 | 3.23 | 0.576 | -1.19 | 0.447 |
Dividends per Share |